This trial is testing whether adding a new drug to standard treatment can improve outcomes for people with hormone receptor-positive, HER2+ metastatic breast cancer.
1 Primary · 7 Secondary · Reporting Duration: 24 months
Active Control
Experimental Treatment
496 Total Participants · 2 Treatment Groups
Primary Treatment: palbociclib · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: